<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362178">
  <stage>Registered</stage>
  <submitdate>29/02/2012</submitdate>
  <approvaldate>8/03/2012</approvaldate>
  <actrnumber>ACTRN12612000276853</actrnumber>
  <trial_identification>
    <studytitle>Comparing immune response to oral polio vaccine administered at short intervals with vaccine administered at standard intervals in healthy newborns in Pakistan</studytitle>
    <scientifictitle>Comparison of Immunogenicity Of Type 1 Monovalent Oral Polio Vaccine (mOPVl) Administered at Short Intervals with Type 1 Monovalent (mOPVl) And Type 1&amp;3 Bivalent (bOPV1&amp;3) Oral Polio Vaccine Given At Standard Intervals in Healthy Newborns in Pakistan: A Randomized Trial; Aga Khan University, Karachi</scientifictitle>
    <utrn>U1111-1128-7348</utrn>
    <trialacronym />
    <secondaryid>None known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>poliomyelitis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Public Health</conditioncode1>
      <conditioncode2>Other public health</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Three intervention arms:
1) Birth tOPV; day 42 mOPV1, day 49 mOPV1, day 79 tOPV, day 107 tOPV
2)  Birth tOPV; day 42 mOPV1, day 56 mOPV1, day 86 tOPV, day 114 tOPV
3) Birth tOPV; day 42 mOPV1, day 72 mOPV1, day 102 tOPV, day 130 tOPV

tOPV: trivalent oral polio vaccine; mOPV1: monovalent type 1 oral polio vaccine
Dose for all oral polio vaccines: two drops</interventions>
    <comparator>One control comparator:
Birth tOPV; day 42 bOPV, day 72 bOPV, day 102 tOPV, day 130 tOPV

bOPV: bivalent oral polio vaccine type 1 and 3 (two drops administered orally)</comparator>
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>A schedule of two doses of mOPV1 administered at a 7 or 14 day interval following a previous mOPV1 dose administered at 42 days induces comparable levels of seroconversion against poliovirus type 1 compared to a schedule of two doses of mOPV1 given at a standard interval of 30 days apart</outcome>
      <timepoint>102 days after study enrollment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>A schedule of two doses of mOPV1 administered at a 7 or 14 day interval following a previous mOPV1 dose administered at 42 days induces comparable levels of seroconversion against poliovirus type 1 compared to a schedule of two doses of bOPV1&amp;3 administered at a standard interval of 30 days apart.</outcome>
      <timepoint>102 days after study enrollment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Infants born healthy (&gt; 2.5 kg birth weight, immediate cry, no neonatal IMCI danger signs) at the study sites (home or health facility births assisted by study-Trained Birth Attendants/other health personnel) and not planning to travel away during entire the study period (birth-102 days).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Days</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Days</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>High-risk newborns will be excluded, as well as newborns requiring hospitalization, birth weight below 2.5 kg, cry &gt;2 minutes, and with any neonatal IMNCI danger signs, residence &gt;30 km from study site, or family is planning to be absent during the birth - 102 day study period. A diagnosis or suspicion of immunodeficiency disorder (either in the participant or in a member of the immediate family - e.g. several early infant deaths, household member on chemotherapy) will render the newborn ineligible for the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/03/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>800</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Pakistan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>WHO</primarysponsorname>
    <primarysponsoraddress>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</primarysponsoraddress>
    <primarysponsorcountry>Switzerland</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>World Health Organization</fundingname>
      <fundingaddress>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</fundingaddress>
      <fundingcountry>Switzerland</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>In order to generate data on 2-dose seroconversion with short interval monovalent OPV1 administration, and standard interval monovalent OPV1 and bivalent OPV (1&amp;3) administration, we will assess additional programmatic options for short-interval SIA rounds in Pakistan and conduct a clinical trial in Karachi, Pakistan where immunogenicity of supplemental mOPV doses in a naive population (newborns) needs objective evaluation.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>WHO ERC</ethicname>
      <ethicaddress>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</ethicaddress>
      <ethicapprovaldate>25/08/2011</ethicapprovaldate>
      <hrec>RPC 454</hrec>
      <ethicsubmitdate />
      <ethiccountry>Switzerland</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Ondrej Mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ondrej Mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</address>
      <phone>+41227911863</phone>
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ondrej Mach</name>
      <address>World Health Organization
Avenue Appia 20
CH-1211 Geneve 27 Suisse</address>
      <phone />
      <fax />
      <email>macho@who.int</email>
      <country>Switzerland</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>